The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study—Analysis of adverse events.
Masayoshi Dazai
No relevant relationships to disclose
Hiraku Fukushima
No relevant relationships to disclose
Yasushi Sato
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Hiroyuki Ohnuma
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Yasushi Tsuji
No relevant relationships to disclose
Yasuyuki Kawamoto
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Masahiko Koike
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Susumu Sogabe
No relevant relationships to disclose
Koshi Fujikawa
No relevant relationships to disclose
Ayumu Hosokawa
No relevant relationships to disclose
Hiroyuki Hisai
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Yuh Sakata
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha